Chime Biologics
Wuhan · Founded 2013
About Chime Biologics
Chime Biologics is a leading global CDMO, focused on ensuring our customers' success in delivering innovative biologic medicines to patients across the world. Chime Biologics can support customers end to end, from pre-clinical support and cell line development through to clinical and commercial manufacturing of drug substance and drug product. Employing our innovative and state-of-the-art development and manufacturing capabilities and proven success in supporting our clients with their clinical and commercial authorizations across the globe, Chime Biologics is a true end-to-end solution provider for the biologics industry. With over 500 skilled employees, we share a common goal to make cutting-edge biomedicines affordable and accessible to patients worldwide, fulfilling our commitment to improving human health globally. About Chime Biologics Europe Innovation Hub The Chime Biologics Europe Innovation Hub is located in Basel, Switzerland, the heart of Europe's biopharmaceutical industry. It is committed to building a bridge for in-depth cooperation between China and Europe in the field of biopharmaceuticals, promoting the efficient connection and collaborative development of innovative resources on both sides. The hub aims to accelerate the empowerment of the rapidly growing Chinese biopharmaceutical innovation ecosystem to the mature European pharmaceutical industry, speeding up the development of large-molecule new drugs and enhancing their affordability and accessibility.
Company Facts
- Founded: 2013
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 501 – 1,000
- Total funding: $332.4M
- Funding stage: Early Stage Venture
- Last round: Series A (Dec 2025)
- Website: chimebiologics.com
- Phone: 278-787-9208
Industries & Categories
Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/chime-biologics-4357 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.